Crispr Therapeutics (CRSP) Stocktwits Mentions Statistics 2025

52 20.9%

1W 13.3% 1M 48.6% 3M 76%

Est. daily mentions on Stocktwits.

Similar companies

Company		Stocktwits Mentions
	Amgen AMGN	23 17.9%
	Gilead Sciences GILD	45 9.8%
	Catalyst Pharmaceuticals CPRX	5 16.7%
	Inovio Pharmaceuticals INO	251 12.6%
	Anavex Life Sciences AVXL	261 15%

Month over Month

Est. daily mentions on Stocktwits.

Mar 2025	66	72.5%
Feb 2025	239	49.6%
Jan 2025	160	10.6%
Dec 2024	145	50.1%
Nov 2024	96

How often is Crispr Therapeutics mentioned on StockTwits?

Crispr Therapeutics was mentioned an estimated 52 times in discussions on StockTwits yesterday.

Analyzing Stocktwits Mentions, how is Crispr Therapeutics performing compared to its industry peers?

Crispr Therapeutics underperforms its industry peers when it comes to Stocktwits Mentions, ranking in the 6th percentile.

What does a high frequency of StockTwits mentions indicate for Crispr Therapeutics' market sentiment?

A high frequency of mentions on StockTwits for Crispr Therapeutics could indicate strong market interest or sentiment towards the company. It often reflects the trading community's engagement with Crispr Therapeutics' stock, potentially signaling bullish or bearish trends based on the context of the discussions.

How often does AltIndex update information on Crispr Therapeutics' mentions on StockTwits?

AltIndex updates the data on Crispr Therapeutics' mentions on StockTwits daily. This frequent update schedule ensures that investors have access to the most current insights into market sentiment and discussion dynamics related to Crispr Therapeutics' on the platform.

About Us

AltIndex revolutionizes investing with advanced alternative data analytics, smart insights, and stock alerts, presented in an easy-to-use dashboard powered by comprehensive company data from across the internet.

Legal Disclaimer
The information provided by AltIndex is solely for informational purposes and not a substitute for professional financial advice. Investing in financial markets carries inherent risks, and past performance doesn't guarantee future results. It's crucial to do your research, consult with financial experts, and align your financial objectives and risk tolerance before investing. AltIndex creators and operators are not liable for any financial losses incurred from using this information. Users should exercise caution, seek professional advice, and be prepared for the risks involved in trading and investing in financial assets, only investing what they can afford to lose. The information in this application, derived from publicly available data, is believed to be reliable but may not always be accurate or current. Users should verify information independently and not solely rely on this application for financial decisions. By using AltIndex, you acknowledge that it doesn't offer financial advice and agree to consult a qualified financial advisor before making investment decisions.